Non‐Melanoma Skin Cancer in Transplant Recipients: A Single‐Centre Retrospective Cohort Study on the Role of Transplant Type, Immunosuppressive Exposure, and Tumor Subtypes
Clinical Transplantation · 2026
DOI: 10.1111/ctr.70451 ↗At a glance
Kohortenstudie in Clinical Transplantation, 2026. Written by Corrado Zengarini and 7 co-authors. Institution: Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. Major MEDLINE topics: Immunosuppressive Agents, Non-Melanoma Skin Neoplasms, Organ Transplantation, Transplant Recipients. 38 references. The full text is freely available (open access, CC BY 4.0). Funded by: Università di Bologna.
Abstract (original language)
Background
Non‐melanoma skin cancer (NMSC) is a frequent long‐term complication in transplant recipients, mainly due to chronic immunosuppression. Its incidence varies by transplant type and regimen, but existing evidence is often fragmented.
Objective
To assess long‐term incidence and risk factors for NMSC, comparing transplant types, immunosuppressive regimens, and tumor subtypes.
Methods
This retrospective cohort comprised 901 transplant recipients (1975–2024) who were under long‐term dermatologic follow‐up. Data on transplant type, immunosuppressive regimen/duration, and tumor subtype were analyzed. NMSC‐free survival was evaluated with Kaplan–Meier curves; Cox regression assessed predictors.
Results
Among 901 transplant recipients, 191 (21.2%) developed at least one NMSC during long‐term follow‐up. Crude incidence rates ranged between 1.88 and 2.68 per 100 person‐years across immunosuppressive drug classes and agents. In multivariable Cox models, older age at first transplant was independently associated with higher NMSC risk (HR 1.07 per year, 95% CI 1.06–1.09, p < 0.001). Sex, transplant group, and ever‐use of individual immunosuppressive agents were not significantly associated with NMSC risk after adjustment.
Conclusion
In this long‐term cohort, NMSC risk increased with age at first transplant, whereas transplant organ and ever‐use of major immunosuppressive agents were not independently associated in adjusted models. Over an extended follow‐up, NMSC accumulated steadily, with crude incidence rates around 1.88–2.68 cases per 100 person‐years across immunosuppressive classes and agents, underscoring the cumulative nature of skin cancer risk under chronic immunosuppression. Our results reinforce the need for sustained, long‐term dermatologic surveillance, particularly in older patients undergoing transplantation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
- Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
- Plastic Surgery Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
- Department of Medical Sciences, Section of Dermatology and Infectious Diseases, University of Ferrara, Ferrara, Italy.
ORCID profiles: Corrado Zengarini
Funding
- Università di Bologna
Cite
APA
Zengarini, C., Tagnin, V., Sorbi, G., Guglielmo, A., La Placa, M., Piraccini, B. M., Pileri, A., & Pignatti, M. (2026). Non‐Melanoma Skin Cancer in Transplant Recipients: A Single‐Centre Retrospective Cohort Study on the Role of Transplant Type, Immunosuppressive Exposure, and Tumor Subtypes. Clinical Transplantation. https://doi.org/10.1111/ctr.70451
Vancouver
Zengarini C, Tagnin V, Sorbi G, Guglielmo A, La Placa M, Piraccini BM, et al. Non‐Melanoma Skin Cancer in Transplant Recipients: A Single‐Centre Retrospective Cohort Study on the Role of Transplant Type, Immunosuppressive Exposure, and Tumor Subtypes. Clinical Transplantation. 2026. doi:10.1111/ctr.70451
BibTeX
@article{Zengarini2026,
author = {Zengarini, Corrado and Tagnin, Vittoria and Sorbi, Gioia and Guglielmo, Alba and La Placa, Michelangelo and Piraccini, Bianca Maria and Pileri, Alessandro and Pignatti, Marco},
title = {Non‐Melanoma Skin Cancer in Transplant Recipients: A Single‐Centre Retrospective Cohort Study on the Role of Transplant Type, Immunosuppressive Exposure, and Tumor Subtypes},
journal = {Clinical Transplantation},
year = {2026},
doi = {10.1111/ctr.70451}
}
EUVIMED